Standards; Enzyme Activators and Inhibitors; Pharmaceutical/API Drug Impurities/Metabolites;
應(yīng)用:
(R)-(3-Methyl-1-(pyrazine-2-carboxamido)butyl)boronic Acid is an impurity of Bortezomib (B675700); the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer.